Paulson Richard A.
President and CEO
Paulson Richard A. has filed 5 SEC Form 4 filings (7 transaction rows) across 1 company, with disclosures dating back to 2025. 5 of those filings fall inside the rolling window. Most recent filing: May 15, 2026.
On the most recent filing, Paulson Richard A. is listed as President and CEO at Karyopharm Therapeutics Inc. Inside the rolling window, Paulson Richard A. reported no open-market purchases and 3 open-market sales totaling $145K in KPTI. The largest disclosed transaction in the window is a sale of 12,361 KPTI shares on Mar 2, 2026, worth $116K.
Companies traded
Other insiders at KPTI
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$145K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Paulson Richard A. made?
Paulson Richard A. has filed 5 SEC Form 4 filings (7 transaction rows) across 1 company since 2025.
Which companies does Paulson Richard A. trade?
Paulson Richard A. has filed SEC Form 4 disclosures for 1 company, including KPTI.
When was Paulson Richard A.'s most recent SEC Form 4 filing?
Paulson Richard A.'s most recent SEC Form 4 filing on Tracefour is dated May 15, 2026.
What is Paulson Richard A.'s job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Paulson Richard A. is listed as President and CEO.
What is Paulson Richard A.'s total buy and sell value in the current window?
Inside the rolling retention window, Paulson Richard A. bought $0 and sold $145K based on SEC Form 4 filings.
What was Paulson Richard A.'s largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 12,361 KPTI shares on 2026-03-02, worth $116K, per SEC Form 4 filings.